Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Sean, Spear, Ella, Sane, Nikhita, Nelson, Adam J., Nerlekar, Nitesh, Segelov, Eva, Nicholls, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632129/
https://www.ncbi.nlm.nih.gov/pubmed/37076569
http://dx.doi.org/10.1038/s41371-023-00831-z
Descripción
Sumario:Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs. [Image: see text]

Ejemplares similares